Highlights:
- Platelet BioGenesis has the world’s first technology to generate clinical-grade human platelets from induced pluripotent stem cells (iPSCs).
- Platelet BioGenesis has been awarded $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop donor-independent platelets as a treatment for radiological and nuclear exposure.